drugset / Trial / NCT04943744
Gastrointestinal STRING Test With Oral Immunotherapy
RandomizedParallel-groupOpen-labelDiagnostic
Summary
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.
Timeline
- Start
- 2021-05-17
- Primary completion
- 2024-05-17
- Completion
- 2024-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | — | — |
| Subject | Omalizumab | Monoclonal antibody | — | — |